ASNS 10-K & 10-Q changes, risk factors and insider trading
Actelis Networks Inc. · OTC · Communications Equipment, Nec · CIK 1141284 · All filings on SEC.gov
At a glance
What changed in the latest 10-K
Risk Factors
Largest changes
“In connection with the Company’s entry into the Common Stock Purchase Agreement with White Lion as described below, if the Company fails to be listed on the Nasdaq Capital Market, the Commitment Fee Amount (as defined below) will increase subject to the terms of the Delisting Penalty Provision in the Common Stock Purchase Agreement. See “Item 1-Business-Recent Developments-Equity Line of Credit Agreement” for additional information.”see in full comparison
“In the course of preparing the financial statements that are included in this Annual Report, management has determined that a material weakness exists within the internal control over financial reporting. The material weakness identified relates to lack of a sufficient number of finance personnel to allow for adequate segregation of duties. …”see in full comparison
“As disclosed in the Notice, the Staff determined that the Company’s common stock failed to maintain compliance with the Bid Price Rule. While companies are typically afforded a 180-calendar-day compliance period to comply with the Bid Price Rule, the Staff concluded that the Company is not eligible for the compliance period pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv) due to the fact that the Company effected a reverse stock split within the prior one-year period, specifically a 1-for-10 reverse stock split on November 18, 2025, and therefore is subject to immediate delisting.”see in full comparison
“On January 26, 2026, Nasdaq filed a rule proposal with the SEC that would permit the immediate suspension and delisting of a company listed on the Nasdaq Capital Market if its market value of listed securities remains below $5 million for 30 consecutive business days. As of the date of this Annual Report, our market value of listed securities is below $5 million and if this rule were to go into effect and we are unable to increase our market value of listed securities above $5 million, we would become subject to immediate suspension and delisting.”see in full comparison
“On August 19, 2025, we received written notice from Nasdaq stating that, due to the Company’s non-compliance with the Minimum Shareholders’ Equity Requirement as of June 30, 2025, and because, pursuant to Listing Rule 5815(d)(4)(B), the Company remained subject to a mandatory hearing panel monitor through August 27, 2025, the Company’s securities were subject to delisting from Nasdaq unless the Company timely requests a hearing before the Panel. The Company has its hearing with the Panel on September 30, 2025.”see in full comparison
“The Company will remain subject to a one-year “Panel Monitor”, as contemplated by Nasdaq Listing Rule 5815(d)(4)(A), through December 5, 2026. If during that period the Company fails to satisfy any of the criteria for continued listing on Nasdaq, the Staff may not grant the Company additional time to regain compliance. Rather, Nasdaq will issue a delist determination, which the Company may address by requesting a new hearing before the Nasdaq Hearings Panel.”see in full comparison
Full comparison: every changed paragraph (40)
We have incurred significant
losses and negative cash flows from operations
and incurred losses of $ 4.4$8.3 million and $6.3$4.4 million for the years ended December 31,
2024 2025 and 2023,2024, respectively. During the years
ended December 31, 20242025 and 2023,2024, we had negative cash flows from operations of
$6.5 $7.7 million and $6.6$6.5 million, respectively. As of
December 31, 2024,2025, our accumulated deficit was $ 44$52 million. We have funded our operations
to date through equity and debt financing and
have cash on hand (including short term bank deposits and restricted cash equivalents) of
$2.3 $4.4 million and long-term restricted cashbank deposits
of $30 thousand and cashlong equivalentsterm and restricted bank depositsdeposit of $0.2$91 millionthousand as of December 31, 2024.
2025. We monitor our cash flow projections on a current
basis and take active measures to obtain the funding it requires to continue our operations.
However, these cash flow projections are
subject to various uncertainties concerning their fulfilment such as the ability to increase
revenues by attracting and expanding its
customer base or reducing cost structure. If we will not succeed in generating sufficient cash
flow or completing additional financing,
then it will need to execute a cost reduction plan that has been prepared. Our transition to
profitable operations is dependent on generating
a level of revenue adequate to support our cost structure. We expect to fund operations
using cash on hand, through operational cash flows
and raising additional proceeds. There are no assurances, however, we will be able
to generate the revenue necessary to support our cost
structure or that we will be successful in obtaining the level of financing necessary
for its operations.
Our
financial condition raises substantial
doubt as to our ability to continue as a going concern.concern
Our
consolidated financial statements have been prepared assuming that
we will continue to operate as a going concern. These events and conditions,
along with other matters, indicate that a material uncertainty
exists that may cast significant doubt on our ability to continue as a
going concern. This going concern determination could materially
limit our ability to raise additional funds through the issuance of
equity or debt securities or otherwise. Further financial statements may include
includes an explanatory paragraph with respect to our ability
to continue as a going concern. There can be no assurance that we will succeed
in generating sufficient revenues from our product sales
to continue our operations as a going concern. If funds are not available to
us, we may be required to delay, reduce the scope of, or
eliminate research or development plans for, or commercialization efforts with
respect to our products. This may raiseraises substantial doubts
about our ability to continue as a going concern.
On
August 25, 2023, we received
a notification letter from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock
Market LLC (“Nasdaq”)
indicating that we are not in compliance with Nasdaq Listing Rule 5550(b)(1) due to our failure to
maintain acomply minimumwith of $2,500,000 in shareholders’ equity (the “Minimum Shareholders’
Equity Requirement”) or
any alternatives to such requirement. In order to maintain our listing on the Nasdaq Capital Market, we submitted
a plan of compliance
addressing how we intended to regain compliance. On March 27, 2024, we received a delist determination letter from
Nasdaq advising us
that the Staff had determined to delist our securities from Nasdaq due to non-compliance with the Minimum Shareholders’
Equity Equity
Requirement, unless we timely request a hearing before the Nasdaq Hearings Panel (the “Panel”). We timely requested
a hearing
before the Panel. On August 27, 2024, we received formal written notice from Nasdaq confirming that we have evidenced compliance with
all applicable criteria for continued listing on Nasdaq as set forth in Nasdaq Listing Rule 5550, including the Minimum Shareholders’
Equity Requirement. In accordance with Nasdaq Listing Rule 5815(d)(4)(B), we will remain subject to a panel monitor for equity compliance
through August 27, 2025.
On August 27, 2024, we received formal written notice from Nasdaq confirming that we have evidenced compliance with all applicable criteria for continued listing on Nasdaq as set forth in Nasdaq Listing Rule 5550, including the Minimum Shareholders’ Equity Requirement. In accordance with Nasdaq Listing Rule 5815(d)(4)(B), we remained subject to a panel monitor for equity compliance through August 27, 2025.
On May 12, 2025, Nasdaq notified us (the “Notification Letter”) that we were not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires our Common Stock to maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”). The Notification Letter had no immediate effect on the listing or trading of our Common Stock on Nasdaq and, at this time, the Common Stock will continue to trade on Nasdaq under the symbol “ASNS”. The Notification Letter provided that we have 180 calendar days, or until November 10, 2025, to regain compliance with the Bid Price Rule.
On August 19, 2025, we received written notice from Nasdaq stating that, due to the Company’s non-compliance with the Minimum Shareholders’ Equity Requirement as of June 30, 2025, and because, pursuant to Listing Rule 5815(d)(4)(B), the Company remained subject to a mandatory hearing panel monitor through August 27, 2025, the Company’s securities were subject to delisting from Nasdaq unless the Company timely requests a hearing before the Panel. The Company has its hearing with the Panel on September 30, 2025.
At the hearing, the Company presented its plan to evidence compliance with the Equity Rule and all other applicable criteria for continued listing on The Nasdaq Capital Market, and requested to remain listed subject to its plan to regain compliance.
AsOn October 28, 2025, we received
ofa listing decision from Nasdaq notifying us that the datePanel of this filing, we believedetermined that wethe areCompany inevidenced compliance with the Minimum Shareholders’
Equity Requirement.
The Panel also granted the Company’s request for continued listing on The Nasdaq Capital Market, pursuant to an exception through December 5, 2025, to regain compliance with the bid price requirement set forth in Nasdaq Listing Rule 5550(a)(1). In order to evidence compliance with the bid price requirement, the Company must evidence a closing bid price of at least $1.00 per share for a minimum of 10, but generally not more than 20, consecutive business days. On November 7, 2025, we held a special meeting of shareholders where our shareholders approved, among other things, the Reverse Split. The Reverse Split was effected on November 18, 2025.
On December 3, 2025, the Company received formal notice from Nasdaq that the Company has regained compliance with the Bid Price Rule and evidenced compliance with all other applicable criteria for continued listing on Nasdaq. Accordingly, the previously disclosed listing matter has been closed.
The Company will remain subject to a one-year “Panel Monitor”, as contemplated by Nasdaq Listing Rule 5815(d)(4)(A), through December 5, 2026. If during that period the Company fails to satisfy any of the criteria for continued listing on Nasdaq, the Staff may not grant the Company additional time to regain compliance. Rather, Nasdaq will issue a delist determination, which the Company may address by requesting a new hearing before the Nasdaq Hearings Panel.
On February 4, 2026, we received a written notice Nasdaq indicating that the Staff has determined to delist the Company’s securities from The Nasdaq Capital Market.
As disclosed in the Notice, the Staff determined that the Company’s common stock failed to maintain compliance with the Bid Price Rule. While companies are typically afforded a 180-calendar-day compliance period to comply with the Bid Price Rule, the Staff concluded that the Company is not eligible for the compliance period pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv) due to the fact that the Company effected a reverse stock split within the prior one-year period, specifically a 1-for-10 reverse stock split on November 18, 2025, and therefore is subject to immediate delisting.
As further disclosed in the Notice, the Company had the right to request a hearing and that a hearing request would result in a stay of any suspension or delisting action pending the conclusion of the hearings process. Accordingly, on February 11, 2026, the Company requested a hearing before the Panel, which served to stay any further suspension or delisting action through the hearing or any extension the Panel provides following the hearing.
At the hearing, the Company intends to take all reasonable measures available and is going to present a plan to regain compliance with the Bid Price Rule and remain listed on Nasdaq to the Panel. However, there can be no assurance that the Company will be able to regain compliance with the Bid Price Rule or maintain compliance with all other Nasdaq continued listing requirements.
In connection with the Company’s entry into the Common Stock Purchase Agreement with White Lion as described below, if the Company fails to be listed on the Nasdaq Capital Market, the Commitment Fee Amount (as defined below) will increase subject to the terms of the Delisting Penalty Provision in the Common Stock Purchase Agreement. See “Item 1-Business-Recent Developments-Equity Line of Credit Agreement” for additional information.
On January 26, 2026, Nasdaq filed a rule proposal with the SEC that would permit the immediate suspension and delisting of a company listed on the Nasdaq Capital Market if its market value of listed securities remains below $5 million for 30 consecutive business days. As of the date of this Annual Report, our market value of listed securities is below $5 million and if this rule were to go into effect and we are unable to increase our market value of listed securities above $5 million, we would become subject to immediate suspension and delisting.
In
addition, on May 20, 2024, Nasdaq notified us that we were not in compliance with the minimum bid price requirements set forth in Nasdaq
Listing Rule 5550(a)(2), which requires our common stock to maintain a minimum bid price of $1.00 per share. On June 20, 2024, we received
a letter from Nasdaq that, for the 10 consecutive business days from June 5, 2024 to June 28, 2024, the closing bid price of the Company’s
common stock had been at $1.00 per share or greater. Accordingly, we have regained compliance with Nasdaq Listing Rule 5550(a)(2) and
Nasdaq considers the prior bid price deficiency matter now closed.
We
have in the past, and may
in the future, be unable to comply with certain of the listing standards that we are required to meet to maintain
the listing of our ordinaryshares
of sharescommon stock on Nasdaq. If we fail to satisfy the continued listing requirements of Nasdaq, such as minimum stockholders’ equity
equity requirements or minimum bid price requirements, Nasdaq may take steps to delist our shares of common stock. Such a delisting would have
have a negative effect on the price of our shares of common stock, impair the ability to sell or purchase our shares of common stock
when persons
wish to do so, and any delisting materially adversely affect our ability to raise capital or pursue strategic restructuring, refinancing
refinancing or other transactions on acceptable terms, or at all. Delisting from Nasdaq could also have other negative results, including
the potential
loss of institutional investor interest and fewer business development opportunities, as well as a limited amount of news
and analyst
coverage of us. Delisting could also result in a determination that our shares of common stock are a “penny stock,” which
which would require brokers trading in our shares of common stock to adhere to more stringent rules, possibly resulting in a reduced
level of
trading activity in the secondary market for our shares of common stock. In the event of a delisting, we would attempt to take actions
actions to restore our compliance with Nasdaq’s listing requirements, but we can provide no assurance that any such action taken
by us would
allow our shares of common stock to become listed again, stabilize the market price or improve the liquidity of our securities, prevent
prevent our shares of common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq’s
Nasdaq’s listing requirements.
On
December 2, 2020, we entered into a loan agreement with Migdalor, or the Migdalor Loan, for a loan of up to approximately $6.0 million. As of the date of this report, we have fully repaid the loan principal, and have an interest outstanding balance of $111,000.
In
February 2024, we entered into a new credit line facility from an
Israeli bank of up to $1.5 million (the “Credit Line”).
The Credit Line is secured by customer invoices and will incur interest
at a Federal SOFR rate plus 5.5%. The Credit Line has been extended
under until February 1, 2026. The current balance outstanding is approximately
$36,000. $574,000.As of the date hereof, the Company has not further extended the credit facility; however, it may do so in the future.
Since
our inception, our
business was focused on serving Telcos for enterprises and residential customers. Our products and solutions have
been deployed with more
than 100 telecommunication service providers worldwide, in enterprise, residential and mobile base station connectivity applications.
applications. In recent years, as we have further developed our technology and rolled out additional products, we turned our focus
on serving the
IoT markets. Our operations are focused on our fast-growing IoT business, while maintaining our commitment to our existing
Telco customers.
A portion of our revenue continues to be derived from our existing Telco customers. For the years ended December 31,
2024 2025 and
December 31, 2023,2024, our Telco customers in the aggregate increaseddecreased by 1% from approximately 27%28% of our revenues in the year ended
ended December 31, 2023,2024, to 28%27% in the year ended December 31, 2024.2025.
We
hold certain patent and
trade secret rights relating to various aspects of our technologies, which are of material importance to the
Company and its future prospects.
Any patents we have obtained or do obtain may be challenged by re-examination or otherwise invalidated
or eventually found unenforceable.
Both the patent application process and the process of managing patent disputes can be time consuming
and expensive. Competitors may attempt
to challenge or invalidate our patents or may be able to design alternative techniques or devices
that avoid infringement of our patents
or develop products with functionalities that are comparable to ours. In the event a competitor
infringes upon our patent or other intellectual
property rights, litigation to enforce our intellectual property rights or to defend
our patents against challenge, even if successful,
could be expensive and time consuming and could require significant time and attention
from our management. We maydo not have sufficient
resources to enforce our intellectual property rights or to defend our patents against
challenges from others.
Patents
have a limited lifespan. In the United States, if all maintenance
fees are paid timely, the natural expiration of a patent is generally
20 years after its first effective nonprovisional filing date. Although
various extensions may be available, the life of a patent, and
the protection it affords, is limited. Given the amount of time required
for the development, testing and regulatory review of new product
candidates, patents protecting such candidates might expire before or
shortly after such product candidates are commercialized. Even
if patents covering our product candidates are obtained, once the patent
life has expired for a product, we may be open to competition
from biosimilar or generic medications. As a result, our patent portfolio
may not provide us with sufficient rights to exclude others
from commercializing product candidates similar or identical to ours. Our
patents issued as of March 20, 2025 will expire on dates ranging
from September 25, 2025up to October 31, 2038, subject to any patent extensions that may be
available for such patents. More specifically,
the following patents will expire over the next three years:, US7606315, US7613235, EP1943827,
EP3459181, GB2556826, MX279453, US7587042,
IDP0030744.
Conditions
Geo-Political conditions in the Middle East
and in Israel, where our research and development facilities are located, may harm our operations.
Our
office where we conduct
our research and development, operations, sales outside the Americas, and administration activities, is located
in Israel. Many of our
employees are residents of Israel. Most of our officers and directors are residents of Israel. Since the establishment
of the State of
Israel in 1948, a number of armed conflicts have taken place between Israel and its neighboring countries, and between
Israel and the
Hamas (an Islamist militiaterror and political group in the Gaza Strip) and, Hezbollah (an Islamist militiaterror and political group
in Lebanon)., and Iran,
including its accomplices.
In
October 2023, Hamas terrorists
infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian
and military targets. Hamas
also launched extensive rocket attacks on Israeli population and industrial centers located along Israel’s
border with the Gaza
Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries and kidnapping
of civilians
and soldiers. Following the attack, Israel’s security cabinet declared war against Hamas and a military campaign against
these terrorist
organizations commenced in parallel to their continued rocket and terror attacks. On January 19, 2025, a temporary ceasefire
went into
effect. effect,On March 18, 2025 the resultceasefire ended with the resumption of whichthe iswar uncertain.between Israel and Hamas.
In
addition, since the commencement
of these events, there have been continued hostilities along Israel’s northern border with Lebanon
(with the Hezbollah terror organization)
and on other fronts from various extremist groups in region, such as the Houthis in Yemen and
various rebel militia groups in Syria and
Iraq. In October 2024, Israel began limited ground operations against Hezbollah in Lebanon,
and in November 2024, a ceasefire was brokered
between Israel and Hezbollah. In addition, Iran recently launched direct attacks on Israel
involving hundreds of drones and missiles and
has threatened to continue to attack Israel and is widely believed to be developing nuclear
weapons. Iran is also believed to have a strong
influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon,
the Houthi movement in Yemen and various
rebel militia groups in Syria and Iraq. These situations may potentially escalate in the future
to more violent events which may affect
Israel and us. Additionally, Yemeni rebel group, the Houthis, launched series of attacks on global
shipping routes in the Red Sea, causing
disruptions of supply chain. Such clashes may escalate in the future into a greater regional conflict. In March 2026, hostilities resumed
conflict.along Israel’s northern border with Lebanon, when Hezbollah resumed its attacks as part of a broader regional escalation. In response,
Israel resumed military operations against Hezbollah in southern Lebanon.
In
connection with the Israeli security cabinet’s declaration of war against Hamas and possible hostilities with other organizations,
several hundred thousand Israeli military reservists were drafted to perform immediate military service.
On February 28, 2026, the
United States and Israel launched coordinated military strikes against Iran, including attacks on strategic military infrastructure and
leadership targets, with the stated aim of degrading Iran’s capacity to conduct or support hostile operations against them. In response,
Iran has fired missiles and drones toward population centers and military installations in Israel, Europe and neighboring countries in
the Gulf region, and also launched counter-strikes against U.S. forces and allied bases throughout the Gulf region As
of the date of this Annual Report,annual
report, we have not been impacted by any absences of personnel at our service providers or counterparties
located in Israel. Military
service call ups that result in absences of personnel from us for an extended period of time may materially
and adversely affect our business,
prospects, financial condition and results of operations. As of the date of this Annualannual Report,report, we
currently have 3839 full-time employees,
with 33 employees located in Israel and 56 employeeemployees located outside of Israel.
The continued political instability and hostilities between Israel and its neighbors and any future armed conflict, terrorist activity or political instability in the region could adversely affect our operations in Israel and adversely affect the market price of our shares of common stock. In addition, several organizations and countries may restrict doing business with Israel and Israeli companies have been and are today subjected to economic boycotts. The interruption or curtailment of trade between Israel and its present trading partners could adversely affect our business, financial condition and results of operations.
We
compute aA significant numberamount of our expenses are presented in Israeli Shekels,
both expenses from employees and suppliers. Our customers buy our products
priced in US dollars or Euros. The strengthening of the shekel
against the dollar and the euro could erode our profitability. For example, the dollar depreciated against the NIS during 2025 by approximately
12.5%. We cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation (if any) of the NIS against the
dollar. If the dollar cost of our operations in Israel increases, our dollar-measured results of operations will be adversely affected.
In
the course of preparing the financial statements that are included in this Annual Report, management has determined that a material weakness
exists within the internal control over financial reporting. The material weakness identified relates to lack of a sufficient number
of finance personnel to allow for adequate segregation of duties. We concluded that the material weakness in our internal control over
financial reporting occurs because as a newly public company, we do not have the necessary business processes, systems, personnel, and
related internal controls necessary to satisfy the accounting and financial reporting requirements of a public company.
We
may not be able to fully remediate the identified material weakness until the steps described above have been completed and our internal
controls have been operating effectively for a sufficient period of time.
As
previously disclosed, during the years ended December 31, 2022 and December 31, 2023, we identified a material weakness in the design
and operation of our internal control over financial reporting in connection with the preparation of our financial statements.
Although
as of December
31, 2024,2025, the materialcompany weaknessesreported inthat ourit has effective internal controlcontrols over financial reporting had been remediated,reporting, there can be no
assurance that we will
not suffer from other material weaknesses or significant deficiencies in the future. If we fail to maintain effective
internal controls over
financial reporting in the future, such failure could result in a material misstatement of our annual or quarterly
financial statements
that would not be prevented or detected on a timely basis and which could cause investors and other users to lose
confidence in our financial
statements, limit our ability to raise capital and have a negative effect on the trading price of our ordinary
shares. Additionally,
failure to remediate the material weakness or otherwise maintain effective internal controls over financial reporting
may also negatively
impact our operating results and financial condition, impair our ability to timely file our periodic and other reports
with the SEC,
subject us to additional litigation and regulatory actions and cause us to incur substantial additional costs in future
periods relating
to the implementation of remedial measures.
We
will beare required to disclose
changes made in our internal controls and procedures on a quarterly basis and our management will beis required
to assess the effectiveness of
these controls annually, beginning with our second annual report on Form 10-K.annually. In addition,
our independent registered public accounting firm will be required to attest to the effectiveness
of our internal controls over financial
reporting pursuant to Section 404, however they will not be required to do so for so long
as we are an emerging growth company.
We could be an emerging growth company for up to five years (i.e., until December 31,
2027). An independent assessment of the
effectiveness of our internal controls over financial reporting could detect problems that our
management’s assessment might not.
Undetected material weaknesses in our internal controls over financial reporting could lead to
restatements of our financial statements
and require us to incur the expense of remediation.
Our
amended and restated
certificate of incorporation, or the Charter, authorizes us to issue up to 42,803,774 shares consisting of
30,000,000 shares of common
stock with a par value of US$0.0001$0.0001 per share, 2,803,774 shares of non-voting common stock with a par
value of US$0.0001$0.0001 per share and 10,000,000
shares of preferred stock with a par value of US$0.0001$0.0001 per share.
As of December 31, 2024,2025, we havehad 8,513,1818,058,392 outstanding shares of common
stock and no outstanding shares of preferred
stock.
In
addition, as of such date,
approximately 98,9323,853 shares
of common stock arewere issuable upon the exercise of outstanding stock options and the173,473 shares vesting of
restricted stock units. Moreover, as of
that date, approximately 99,2986,750 shares of our common stock are available for future grants under
our stock incentive plan
and for future purchase under our employee stock purchase plan. In addition, as of such date, up
to $1.3 million ofnone shares of
common stock are issuable pursuant to our ATM Program with
HCW.
Management's Discussion & Analysis (MD&A)
New heading “July 2025 Private Placement”
New heading “September 2025 Warrant Inducement”
New heading “Equity Line of Credit Agreement”
New heading “White Lion Private Placement”
New heading “December 2025 Offering”
Removed heading “Marketable securities”
Largest changes
“Rodman & Renshaw LLC and HCW acted as financial advisors to the Company in connection with the transactions contemplated by the Inducement Letter. Pursuant to an engagement letter with HCW, the Company has agreed to pay the financial advisors a cash fee equal to 7.0% of the aggregate gross proceeds received from the Holder’s exercise of the Existing Warrants, as well as a management fee equal to 1.0% of the gross proceeds from the exercise of the Existing Warrants and $25,000 paid for non-accountable expenses. …”see in full comparison
Full comparison: every changed paragraph (65)
We
are a market leader in cyber-hardened, rapid-deployment networking solutions for wide-area IoT applications including federal, state
and local government, ITS, military, utility, rail, telecom (notably in multi-dwelling units) and campus applications. Additionally,
through our “Cyber Aware Networking” initiative, we provide an AI-based cyber monitoring and protection software-based system
for all edge devices, enhancing network security and resilience and operational continuity.
Actelis Networks, Inc. (“Actelis,”
“we,” “us,” “our,” “the Company,” “our company”) is a market leader in cyber-hardened,
rapid-deployment networking solutions for wide-area IoT applications including federal, state and local government, intelligent traffic
systems (“ITS”), military, utility, rail, telecom and campus applications. Our
unique portfolio of hybrid fiber, environmentally
hardened aggregation switches, high density Ethernet devices, advanced management software
and AI-basedcyber-protection cyber-security offering,capabilities, unlocks
the hidden value of essential networks and the devices they connect,networks, delivering a safe
and cyber-awaresafer connectivity for rapid, cost-effective deployment.
Our
networking solutions
use a combination of newly deployed fiber infrastructure and existing copper and coaxial lines which our patented
technology can upgrade
to Fiber-grade to jointly create what we believe to be a highly cost-effective, securesecure, and quick-to-deploy network.
Our patent protected
hybrid hybrid-fiberfiber networking solutions deliver excellent communication over fiber to locations that may be easy to reach
with new fiber. However,
for locations that are difficult, or too costly to reach with fiber, we can upgrade existing copper or coax
lines to deliver cyber-hardened, high-speed
connectivity without needing to replace the existing copper infrastructure with new fiber. We believe
that such hybrid fiber copper networking
solution solutions havehas distinct advantages in most real-life installations, while providing significant budget
savings and accelerating deployment
of modern IoT networks. Based on our experience, most IoT projects have challenging, hard to reach
with fiber locations which may significantly increase explode
such projects’ timeline and budgets. We believe that our solutions can provide
connectivity over either fiber, copperfiber or coaxcopper with speeds
of up to multi-Gigabit communication, while supporting Fiber-grade reliability
and quality.
A primary focus of ours is to provide our customers with a cyber-secure network solution. We currently offer Triple-Shield protection of data delivered with coding, scrambling and encryption of the network traffic. We also provide secure, encrypted access to our network management software, and are working to further enhance system-level and device-level software protection. We are also working to introduce additional capabilities for network-wide cyber protection software as an additional SW and license-based services.
Our
IoT cyber-security software solution implements AI to monitor, identify vulnerabilities and threats, offers or implements automatically
AI generated plans addressing such exposures and constant reporting of all such activities, for the sake of documentation and compliance.
This solution comes with the network itself, and uses the network traffic to become cyber-aware of the risks imminent to the IoT devices
that are connected to that network.
When
high speed, long reach,
reliable and secure connectivity is required, network operators usually resort to using wireline communication
over physical communication
lines such as fiber, coaxcoax, and copper, rather than wireless communication that is more limited in performance,
reliability, reach and
security. However, new fiber wireline infrastructure is costly to deploy, involves lengthy civil works to install,
and, based on our internal
calculations, often accounts for more than 50% of total cost of ownership (ToC) and time to deploy wide-area
IoT projects.
Providing
new fiber connectivity
to hard-to-reach locations is especially costly and time-consuming, often requiring permits for boring, trenching,
and right-of-way, sometimes
done over many miles. Connecting such hard-to-reach locations may cause significant delays and budget overruns
in IoT projects. Our solutions
aim to solve these challenges by instantly enhancing performance of such existing copper and coax infrastructure
to fiber-grade performance,
through the use of advanced signal processing aand unique, patented network architecture, without the need to
run new fiber to hard-to-reach
locations; thus, effectively accelerating deployment of many IoT projects, as we estimate, sometimes from
many months to only days. The
result for the network owner is a hybrid network that optimizes the use of both new Fiber (where
available) as well as upgraded, fiber-grade
copper and coax that is now modernized, digitized and cyber-hardened. This unique hybrid
network approach is making IoT projects often
significantly more affordable, fast to deploy and predictable to plan and budget. The same
is correct in multi-dwelling unit buildings where the wiring from the roof (in case of a wireless based connectivity) or from the basement
in case of a wired connectivity to the building. In such cases we utilize existing in-building wiring, preventing the need for brand-new
ones and enables multi-gigabit connectivity to each apartment or suite.
In
addition, our solutions
can also provide power over existing copper and coax lines to remotely power up network elements and IoT components
connected to them
(like cameras, small cell and Wi-Fi base stations sensors etc.). Connecting power lines to millions of IoT locations
can be costly and
very time consuming as well (similar to data connectivity, for the same reason-needreason — need for civil works). By offering the ability
ability to combine power delivery over the same existing copper and coax lines that we use for high-speed data, we believe our solutions
are solving
yet another important challenge in connecting hard-to-reach locations. We believe that combining communication and power
over the same
existing lines is particularly important to help connect many fifth generation, or 5G, small cells and Wi-Fi base stations,
as high cost
of connectivity and power is often slowing their deployment.
Since
our inception, our
business was focused on serving telecommunication service providers, also known as Telcos, to provide connectivity
for enterprises and
residential customers. Our products and solutions have been deployed with more than 100 telecommunication service
providers worldwide,
in enterprise, residential and mobile base station connectivity applications. In recent years, as we have further
developed our technology
and introduced additional products, we turned our focus on serving the wide-area IoT, federal and DoDDoW markets,
as well as MDUs,multi-dwelling
units, and introduced, in 2024, our cyber-aware networking solutions for IoT markets as well.
Our
operations are focused
on our fast-growing IoT, federal and DoDDoW markets, Intelligent Transportation and MDUs while maintaining our commitment to our existing Telco customers,
and particularly MDUs.customers. In 2024, we introduced new product offering, some of which could serve both the IoT markets and our Telco customers.
We
derive a majority of our
revenues from our existing and new IoT (including federal and DoDDoW) customers. For the years ended December
31, 20242025 and December 31, 2023,
2024, our IoT customers in the aggregate accounted for approximately 72%73% and 73%72% of our revenues, respectively.
In
December 2020, we entered into the Migdalor Loan, for a loan of up to approximately $6.0 million. In February 2024, we performed a partial
early repayment of Migdalor Loan in the amount of 2.0 million NIS (approximately $550,000). During April and May 2024, we made
an additional partial early repayment of Migdalor loan in the amount of NIS 10.9 million (approximately $2.9 million).
In
May 2024, we signed an amendment to the agreement with Migdalor, pursuant to which the remaining $470,000 of the one-time interest
payment which was originally due in January 2024 to Migdalor, will be paid in 12 equal monthly payments bearing 9.6% interest from
February 2024 until February 2025. In addition, we are obligated to issue Migdalor warrants to acquire common stock of the Company for
up to $150,000, based on a share price as of February 8, 2024.
As
of the date of this report, we have fully repaid the loan principal, and we have an interest outstanding balance of $111,000.
In February 2024, we entered
into the Credit Line, which increased our operating liquidity while not increasing our total debt, as we will perform an early repayment
of our existing debt using our restricted cash in a similar amount.Line. The Credit Line
is secured by customer invoices and incurs interest
at a Federal SOFR rate plus 5.5%. The Credit Line has beenwas extended underuntil February 1, 2026.
As of the date hereof, the Company has not further extended the credit facility; however, it may do so in the future.
The Credit Line balance drawn
is examined every month andmonth, adjusted up to every three months, and the repayment of the Credit Line will beis made up to every three months subject
subject to the expiration of the financing period for the invoices that were financed. We may refinance newly issued invoices at any time
up to
the Credit Line limit and subject to the terms of the Credit Line. As of December 31, 2024, we used $0.8 million of the Credit Line,
and2025 the current balance outstanding is approximately $529,000.
$479,234.
Our
revenues for the year
ended December 31, 20242025 amounted to $7.8$3.7 million, compared to $5.6$7.8 million for the year ended December 31, 2023.
2024. The increasedecrease was primarily
attributable to increasesoftware and services renewal last year for 2 years which will be up for renewal in 2027, as well as a large deal to the
City of salesWashington inD.C. Northlast Americayear, region,while it is primarily attributable to an increase of
134% of2025’s revenues generatedare frommore Northbackend America and a decrease of 42% and 61% of revenues generated from Europe, the Middle East and Africa
respectively compared to last year.loaded.
Our
cost of revenues for
the year ended December 31, 2025, amounted to $2.5 million compared to $3.5 million for the year ended December 31, 2024, amounted to $3.5 million compared to $3.7 million for the year ended December
31, 2023.2024. The decrease
from the corresponding period was primarily attributable to the change in regional mix of revenue of an increase
in North America revenues, which are more profitable, and a decrease in Europe,sales Middlewhich Eastled to a decline in variable costs and Africafixed revenuescost
remaining which are less profitable
as well as indirect costs not increasing significantly with revenues growing.constant.
Our
research and development expenses for the year ended December 31, 2024,
2025, amounted to $2.4$2.6 million compared to $2.7$2.4 million for the year
ended December 31, 2023.2024. The decreaseincrease is primarily attributabledue to costthe reductionstrengthening
of measuresthe taken.Israeli shekel against the U.S. dollar which led to an increase in expenditure by approximately $151,000.
Our
sales and marketing expenses for the year ended December 31, 2024, 2025,
amounted to $2.6$2.9 million compared to $3.0$2.6 million for the year ended December
31, 2023.2024. The decreaseincrease was mainlyprimarily dueattributable to costengaging
consultants reductionto measuresexpand taken.market reach in primarily the government sector.
Our
general and administrative
expenses for the year ended December 31, 2024,2025, amounted to $3.2$2.9 million compared to $3.5$3.2 million for the year
ended December 31, 2023.2024. The
decrease was mainly due to cost reduction measures taken.taken, while these benefits were offset by higher costs driven by the strengthening
of the Israeli shekel against the U.S. dollar.
Our
OtherWe had no other Income for
the year ended December 31, 2025, compared to $163,000 for the year ended December 31, 2024,2024. amountedThe income in 2024 is related to approximately $160,000, compared to none for the year ended December 31,government
2023. The increase is driven by a government grant from the State of Israel associated with the Iron Swords war, received during the
second quarter of 2024.war.
Our
operating loss for the
year ended December 31, 2024,2025, was $3.8$7.2 million, compared to an operating loss of $7.4$3.8 million for the year ended
December 31, 2023.2024. The decrease
increase was mainly due to the increasedecline in revenues,sales, improvedwhile grossoperating marginexpenditure dueremained to regional revenue mix,consistent and cost
reduction measures taken, reducingincreased operating expenses.expenses by
$0.3 million driven by the strengthening of the Israeli shekel against the U.S. dollar by approximately 7%.
Our
financial expenses, net for the year ended December 31, 2024,2025, was
approximately $620,000$1.08 million of interest expense
expense, compared to $1.1 million (including approximately $800,000 in interest expenses)$620,000 for the year ended December 31, 20232024 The increase is
mainly due
to expenditure of $750,000 related to financialthe incomeCommitment Fee under the Common Stock Purchase Agreement payable in thecommon priorshares year from bank deposits, increase due to warrant valuation and exchange rate differences
not repeated in current period.issuance.
Our net loss for the year
ended December 31, 20242025 was $4.4$8.3 million, compared to
a net loss of $6.3$4.4 million for the year ended December 31, 2023.2024. This decreaseincrease was primarily attributable to lower sales while operating
primarilyexpenditure remained consistent, as well as due to a one-time financial commitment expenditure of $750,000. In addition, the Israeli shekel
strengthened by an average of 7% against the U.S. dollar, leading to higher operating expenses and contributing to increase in revenues,net improved gross margin due to regional revenue mix, and cost reduction measures taken, reducing
operating expenses, partially offset by financial income in the prior year not repeating itself.loss.
July 2025 Private Placement
On June 30, 2025, we entered into the July 2025 Purchase Agreement with certain accredited Investors, pursuant to which we agreed to issue and sell to the Investors in the July 2025 Private Placement (a) 162,602 shares of Common Stock, (b) Series A-3 Warrants to purchase up to 162,602 shares of Common Stock, and (c) Series A-4 Warrants to purchase up to 325,204 shares of Common Stock, for a purchase price of $6.15 per share and related July 2025 Common Warrants, for a total aggregate gross proceeds of approximately $1 million. The July 2025 Private Placement closed on July 2, 2025.
The Series A-3 Warrants have an exercise price of $6.15 per share, are exercisable commencing on the July 2025 Shareholder Approval Date and expire five years following the July 2025 Shareholder Approval Date. On November 7, 2025, the July 2025 Shareholder Approval was obtained in a special meeting of our shareholders, resulting in the July 2025 Shareholder Approval Date being such date.
The Series A-4 Warrants have an exercise price of $6.15 per share, are exercisable commencing on the July 2025 Shareholder Approval Date and expire eighteen months following the July 2025 Shareholder Approval Date.
HCW acted as the Placement Agent for the issuance and sale of the Securities. The Company has agreed to pay an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from the Offering and $35,000 for accountable expenses to the placement agent. The Company also agreed to issue to the Placement Agent, or its designees, July 2025 Placement Agent Warrants to purchase up to 7.0% of the aggregate number of the shares of Common Stock sold to the Investors (or warrants to purchase up to 11,382 shares of Common Stock) at an exercise price per share of $7.688 which will be exercisable commencing on the July 2025 Shareholder Approval Date and a have term of five years after the July 2025 Shareholder Approval Date.
September 2025 Warrant Inducement
On
June 5,September 2024,2, 2025, we entered
into anthe inducementInducement agreementLetter with a certain holderHolder of certain of ourthe existingCompany’s warrantsExisting Warrants to purchase upan to an
aggregate of 999,670427,020 shares
of the Company’s common stock, consisting of our(i) common127,119 stock originallywarrants issued on MayDecember 8,20, 2023,2023 with aan fiveexpiration anddate one-halfof yearJune term,20,
2029 at an exercise
price of $2.75$11.8 per share (theii) “May99,967 2023warrants Warrants”issued on June 6, 2024 with an expiration date of December 6, 2029 at
an exercise price of $20.00 per share and (iii). 199,934 warrants issued on July 2, 2024 with an expiration date of July 2, 2026 at an
exercise price of $17.50 per share.
Pursuant
to the inducement agreement, the holder agreed to exercise for cash its May 2023 Warrants to purchase an aggregate of 999,670 shares
of our common stock at an exercise price of $2.75 per share, in consideration of our agreement to issue new common stock purchase warrants
(the “June 2024 Warrants”), as described below, to purchase up to an aggregate of 1,999,340 shares of our common stock, at
an exercise price of $2.00 per share.
H.C.
Wainwright & Co., LLC (the “Placement Agent”) acted as our exclusive placement agent in connection with the June 2024
Warrant Inducement. In connection with the June 2024 Warrant Inducement, we issued to certain designees of the Placement Agent warrants
(the “June 2024 Placement Agent Warrants”) to purchase up to 69,977 shares of common stock (representing 7.0% of the Existing
Warrants being exercised), which have the same terms as the June 2024 Warrants, except that the Placement Agent Warrants have an exercise
price equal to $3.4375 per share (125% of the exercise price of the May 2023 Warrants). The June 2024 Warrants were immediately exercisable
from the date of issuance, until five and one-half year anniversary of such date for 999,670 of the June 2024 Warrants, and until twenty
four months anniversary of such date for the remaining 999,670 of the June 2024 Warrants. The Placement Agent Warrants are immediately
exercisable from the date of issuance, until the five and one-half year anniversary of such date. The closing of the June 2024 Warrant
Inducement occurred on June 6, 2024.
On
June 30, 2024, we entered into an inducement letter with a holder of our June 2024 Warrants, to purchase up to an aggregate of 999,670
shares of the June 2024 Warrants, originally issued on June 6, 2024, with a twenty-four month term, at an exercise price of $2.00 per
share.
Pursuant
to the inducement letter,Inducement
Letter, the holderHolder agreed to exercise for cash itsthe warrantsExisting Warrants to purchase an aggregate of 999,670427,020 shares of ourthe Company’s
common
stock at ana reduced exercise price of $2.00$3.70 per share,share in consideration of ourthe Company’s agreement to issue new common stock purchase warrants (the “JulyNew Warrants,
2024 Warrants”), as descried below, to purchase up to an aggregate of 1,999,340640,530 sharesNew of our common stock (the “July 2024
Warrant Shares”), at an exercise price of $1.75$3.70 per share. The Company received
aggregate gross proceeds of approximately $1.6 million from the exercise of the Existing Warrants by the Holder, before deducting financial
advisory fees and other offering expenses payable by the Company.
Rodman & Renshaw LLC and HCW acted as financial advisors to the Company in connection with the transactions contemplated by the Inducement Letter. Pursuant to an engagement letter with HCW, the Company has agreed to pay the financial advisors a cash fee equal to 7.0% of the aggregate gross proceeds received from the Holder’s exercise of the Existing Warrants, as well as a management fee equal to 1.0% of the gross proceeds from the exercise of the Existing Warrants and $25,000 paid for non-accountable expenses. The Company has also agreed to issue to the financial advisors or their designees the Inducement Placement Agent Warrants to purchase up to 29,891 shares of common stock (representing 7.0% of the Existing Warrants being exercised), which will have the same terms as the New Warrants having a term of five years of Stockholder Approval (as defined below) except the Inducement Placement Agent Warrants will have an exercise price equal to $4.625 per share (125% of the exercise price of the Existing Warrants).
The New Warrants have an exercise price equal to $3.70 per share. The New Warrants will be exercisable from the effective date (the “Warrant Stockholder Approval Date”) of shareholder approval (“Stockholder Approval”), until (i) the five-year anniversary of such date for 340,629 of the New Warrants and (ii) the twenty-four-month anniversary of such date for 299,901 of the New Warrants. The exercise price and number of New Warrant Shares issuable upon exercise of the New Warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, subsequent rights offerings, pro rata distributions, reorganizations, or similar events affecting the Company’s common stock and the exercise price. On November 7, 2025, the Warrant Stockholder Approval was obtained in a special meeting of our shareholder, resulting in the Warrant Stockholder Approval Date being such date.
The closing of the transactions contemplated pursuant to the Inducement Letter occurred on September 3, 2025.
Provided that the Inducement Letter prohibited the Company from entering into an agreement to effect any issuance by the Company involving a variable rate transaction, the Holder agreed to waive such prohibition with respect to the transactions contemplated by the ELOC Purchase Agreement, and signed an amendment to the Inducement Letter on October 9, 2025. Pursuant to such amendment, the Company issued to the Holder 10,000 warrants to purchase shares of common stock of the Company on similar terms as the Series A-1 Warrants.
Equity Line of Credit Agreement
On September 27, 2025, we entered into the Common Stock Purchase Agreement, with an effective date of October 1, 2025, and a related White Lion RRA with White Lion. Pursuant to the Common Stock Purchase Agreement, the Company has the right, but not the obligation to require White Lion to purchase, from time to time, up to $30,000,000 in aggregate Commitment Amount of newly issued shares of the Company’s Common Stock, subject to certain limitations and conditions set forth in the Common Stock Purchase Agreement.
As consideration for White Lion’s irrevocable commitment to purchase the Company’s Common Stock up to the Commitment Amount, the Company agreed to issue shares of Common Stock to White Lion (the “Commitment Shares”) equal to $750,000 (the “Commitment Fee Amount”) divided by the lowest traded price of the Company’s common stock during the 30 business days prior to the issuance of the Commitment Shares. Upon mutual agreement with White Lion, the Company issued 1,704,545 pre-funded warrants to purchase shares of Common Stock exercisable into the Commitment Shares on December 31, 2025.
White Lion Private Placement
Concurrently on September 27, 2025, the Company entered into the PIPE Purchase Agreement with White Lion, pursuant to which the Company agreed to issue and sell to White Lion in a private placement (the “Offering”) (i) 87,177 shares of Common Stock, and (ii) White Lion Pre-Funded Warrants to purchase up to 312,823 shares of Common Stock (for a purchase price of $2.125 per share of Common Stock and $2.124 per White Lion Pre-Funded Warrant, for a total aggregate gross proceeds of approximately $850,000. The Offering closed on September 29, 2025.
The Company had a right to redeem 48,826 of the shares of Common Stock at a redemption price of $0.001 per share. The Company and White Lion have agreed that, in lieu of such redemption, on October 20, 2025, the Company reduced the number shares issuable pursuant upon exercise of the White Lion Pre-Funded Warrants by 48,826 shares, to 263,997.
The White Lion Pre-Funded Warrants are immediately exercisable at an exercise price of $0.001 per share of Common Stock and will not expire until exercised in full. However, the Company may not issue a number of shares of Common Stock pursuant to exercise of the White Lion Pre-Funded Warrants in an amount that will not exceed the Exchange Cap when combined with the number of Shares issued in the Offering, before shareholder approval for further issuance beyond the Exchange Cap is obtained. The Company intends to obtain such shareholder approval concurrently with the Shareholder Approval required for the issuance of shares of Common Stock under the Common Stock Purchase Agreement beyond the Exchange Cap.
December 2025 Offering
On December 17, 2025, we offered and sold in the December 2025 Offering (i) 4,352,500 shares of the Company’s Common Stock, (ii) 1,897,500 December 2025 Pre-Funded Warrants, and (iii) 6,250, December 2025 Common Warrants, at a purchase price of $0.80 per share of Common Stock and accompanying December 2025 Common Warrant, and $0.7999 per December 2025 Pre-Funded Warrant and accompanying December 2025 Common Warrant. Aggregate gross proceeds from the December 2025 Offering (without taking into account any proceeds from any future exercises of December 2025 Warrants) were approximately $5 million. The Offering closed on December 19, 2025.
The December 2025 Pre-Funded Warrants are immediately exercisable at an exercise price of $0.0001 per share of Common Stock and will not expire until exercised in full.
Each December 2025 Common Warrant has an exercise price of $0.80 per share, is exercisable immediately on upon issuance and will expire on the five-year anniversary of the date of issuance.
HCW acted as the sole placement agent, on a “best efforts” basis, in connection with the Offering. On March 3, 2025, the Company and HCW had entered into the Engagement Agreement with the Company to serve as exclusive underwriter, agent or advisor in any offering of securities of the Company for a six-month term. The Engagement Agreement has been extended twice since its initial effectiveness and currently runs through March 12, 2026 . Under the Engagement Agreement, as extended, the Company agreed to pay the Placement Agent an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company in the Offering, as well as a management fee equal to 1.0% of the gross proceeds raised in the Offering. The Company also agreed under the Engagement Agreement to reimburse the Placement Agent $25,000 for non-accountable expenses and up to $100,000 for fees and expenses of legal counsel and other out-of-pocket expenses of the Placement Agent in connection with the Offering. Pursuant to the Engagement Agreement, the Company will issue to the Placement Agent or its designees 437,500 December 2025 Placement Agent Warrants to purchase up to 437,500 shares of Common Stock, representing 7.0% of the sum of the Shares and Pre-Funded Warrants to be sold in the Offering. The December 2025 Placement Agent Warrants have an exercise price of $1.00 per share of Common Stock (representing 125% of the public offering price per Share and accompanying Common Warrant), are exercisable for five years from the date of the commencement of sales in this offering, and otherwise reflect substantially the same terms as the December 2025 Common Warrants. The Engagement Agreement contains representations, warranties, indemnification and other provisions customary for transactions of this nature.
The net proceeds to the Company from the December 2025 Offering are approximately $4.46 million after deducting placement agent fees and estimated offering expenses payable by the Company. The Company intends to use the proceeds from the Offering for general corporate purposes.
We
engaged the Placement Agent to act as our exclusive placement agent in connection with the July 2024 Warrant Inducement. In connection
with the July 2024 Warrant Inducement, we issued to certain designees of the Placement Agent warrants (the “July 2024 Placement
Agent Warrants”) to purchase up to 69,977 shares of common stock (representing 7.0% of the Existing Warrants being exercised),
which have the same terms as the July 2024 Warrants, except that the Placement Agent Warrants have an exercise price equal to $2.50 per
share (125% of the exercise price of the June 2024 Warrants). The July 2024 Warrants were immediately exercisable from the date of issuance,
until twenty four months anniversary of such date. The July 2024 Placement Agent Warrants are immediately exercisable from the date of
issuance, until the five and one-half year anniversary of such date. The closing of the July 2024 Warrant Inducement occurred on July
2, 2024.
As
of December 31, 2024, 2025,
our accumulated deficit was $44$52 million. We have funded our operations to date through equity and debt financing
and have cash on hand
(including short term bank deposits and restricted cash equivalents) of $2.3$4.4 million and long-term restricted cash
and cash equivalents and restricted bank deposits of $0.2$30 millionthousand
and long term deposit of $91 thousand as of December 31, 2024.2025. We monitor our cash flow projections
on a current basis and take active
measures to obtain the funding it requires to continue our operations. However, these cash flow projections
are subject to various uncertainties
concerning their fulfilment such as the ability to increase revenues by attracting and expanding
its customer base or reducing cost structure.
If we are not successful in generating sufficient cash flow or completing additional financing,
including debt refinancing which shall
release restricted cash, then we will need to execute a new cost reduction plan in addition to
previous cost reduction plans that were
executed so far. Our transition to profitable operations is dependent on generating a level of
revenue adequate to support our cost structure.
We expect to fund operations using cash on hand, through operational cash flows and raising
additional proceeds. There are no assurances,
however, that we will be able to generate the revenue necessary to support our cost structure
or that we will be successful in obtaining
the level of financing necessary for our operations. Management has evaluated the significance
of these conditions and has determined
that we do not have sufficient resources to meet our operating obligations for at least one year
from the issuance date of these consolidated
financial statements. These conditions raise substantial doubt as to our ability to continue
as a going concern. These consolidated financial
statements have been prepared assuming that we will continue as a going concern and
do not include any adjustments that might result from
the outcome of this uncertainty.
Cash
used in operating activities
(including the effect of exchange rate changes on cash and cash equivalents and restricted cash) amounted to $7.7 million for the year
ended December 31, 2025, compared to $6.5 million for the year ended December 31, 2024,2024. comparedThe toincrease $6.3 million forfrom the yearcorresponding ended December 31, 2023. The decrease in
cash used in operating activitiesperiod was
mainly due to costlower reduction measures taken.sales.
Net
cash providedused by investing
activities was $197,000$8,000 for the year ended December 31, 2024,2025, compared to cash provided by investing activities
of $3.8 million$197,000 for the year
ended December 31, 2023.2024. The increasedecrease from the corresponding period was mainly due
to the reduction in short-term bank deposits.
Net cash provided by financing activities was $9.8 million for the year ended December 31, 2025, compared to $3.1 million for the year ended December 31, 2024. The increase from the corresponding period was mainly driven by proceeds from sales of common stocks in an at the market (ATM) offering, proceeds from private placements which occurred in July and September 2025, a follow-on securities offering which occurred in December 2025 and proceeds from a warrant inducement transaction which occurred in September 2025.
Net
cash provided by financing activities was $3.1 million for the year ended December 31, 2024, compared to $3.8 million for the year
ended December 31, 2023. The decrease is related to the repayment of long-term loan, offset by funds raised from an investor warrant
exercise. See notes 2 to the condensed consolidated financial statements
Critical
judgement and
estimates have been used primarily in estimating revenues the fair value of our financial instruments (for
example, warrants, notes and stock options), as well as the estimate of future usage of existing inventory to determine the net
value value
of our inventory (see notes in financial statements).
What changed in the latest 10-Q
Risk Factors
Full comparison: every changed paragraph (2)
We also intend to apply to
list our Common Stock for up-listing back onto the Nasdaq Capital Market. We do not currently meet all of the requirements for initial
listing, and may not meet all of the requirements for uplisting in the future. We hope to list our Common Stock on the Nasdaq Capital
Market in the future and expect that a reverse stock split will be necessary for us to meet the minimum bid price and/or minimum closing
stock price requirements of Nasdaq. We may not be able to meet the initial listing standards of the Nasdaq Capital Market, even after
a reverse stock split, may meet such listing standards without having to affecteffect a reverse stock split, and/or may have our application
to Nasdaq rejected.
In addition, since the commencement of these events, there have been continued hostilities along Israel’s northern border with Lebanon (with the Hezbollah terror organization) and on other fronts from various extremist groups in the region, such as the Houthis in Yemen and various rebel militia groups in Syria and Iraq. In October 2024, Israel began limited ground operations against Hezbollah in Lebanon, and in November 2024, a ceasefire was brokered between Israel and Hezbollah. In addition, Iran recently launched direct attacks on Israel involving hundreds of drones and missiles and has threatened to continue to attack Israel and is widely believed to be developing nuclear weapons. Iran is also believed to have a strong influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria and Iraq. These situations may potentially escalate in the future to more violent events which may affect Israel and us. Additionally, Yemeni rebel group, the Houthis, launched series of attacks on global shipping routes in the Red Sea, causing disruptions of supply chain. Such clashes may escalate in the future into a greater regional conflict. In March 2026, hostilities resumed along Israel’s northern border with Lebanon, when Hezbollah resumed its attacks as part of a broader regional escalation. In response, Israel resumed military operations against Hezbollah in southern Lebanon.
Management's Discussion & Analysis (MD&A)
New heading “Amendment to Equity Line of Credit”
Removed heading “The following discussion and analysis should be read in conjunction with our condensed consolidated financial statements and related Notes included elsewhere in this Quarterly Report on Form 10-Q and the Consolidated Financial Statements and related Notes contained in our Annual Report on Form 10-K for the year ended December 31, 2025.”
Removed heading “Cautionary Note Regarding Forward-Looking Statements”
Removed heading “Recent Developments”
Removed heading “Nasdaq Delisting”
Removed heading “Issuer Purchases of Equity Securities”
Removed heading “Binding Term-sheet with Exaware”
Largest changes
“On July 1, 2026, the Company and White Lion entered into the Amendment to the ELOC Purchase Agreement pursuant to which the Company agreed to issue to White Lion an aggregate of 9,850,000 shares of common stock (the “Amendment Commitment Securities”) in exchange for White Lion’s right to receive shares of common stock under the Commitment Shares provisions and the Delisting Penalty Provision due to the Company’s delisting from the Nasdaq Capital Market in April 2026. …”see in full comparison
To the extent additional funds are necessary to meet our long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of additional indebtedness, additional equity financings or a combination of these potential sources of funds; however, such financing may not be available on favorable terms, or at all. In particular, our delisting from thesee in full comparisonwarNasdaq Capital Market to the OTCQB limits our ability to raise equity, which will remain limited if we are unsuccessful inIsraelre-listing on Nasdaq. Additionally, the wars in the Middle East and the war between Russia and the Ukraine,hashave resulted in, and may continue to result in, significant disruption of global financial markets, reducing our ability to access capital.
“If at any point during the term of the ELOC Purchase Agreement the Company failed to be listed on the Nasdaq Capital Market, the Commitment Fee Amount will increase to $1,000,000 if remedied within six months or less, to $1,250,000 if remedied after six months but before twelve months, and $1,500,000 if not remedied within twelve months (the “Delisting Penalty Provision”).”see in full comparison
“Subject to the satisfaction of certain customary conditions including, without limitation, the effectiveness of a registration statement registering the shares issuable pursuant to the ELOC Purchase Agreement, the Company’s right to sell shares to White Lion will commence on the Commencement Date and extend until 36 months through the Commitment Period, unless the Company has exercised its right in full to sell shares to White Lion under the ELOC Purchase Agreement prior to such date. …”see in full comparison
“On February 4, 2026, the Company received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq staff (the “Staff”) had determined to delist the Company’s securities from The Nasdaq Capital Market. As disclosed in the Notice, the Staff determined that the Company’s common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, in violation of Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). …”see in full comparison
Full comparison: every changed paragraph (66)
The following discussion
and analysis should be read in conjunction with our condensed consolidated financial statements and related Notes included elsewhere in
this Quarterly Report on Form 10-Q and the Consolidated Financial Statements and related Notes contained in our Annual Report on Form
10-K for the year ended December 31, 2025.
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form
10-Q includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the
“Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that
are not historical facts and involve risks and uncertainties that could cause actual results to differ materially from those expected
and projected. All statements other than statements of historical fact included in this Form 10-Q including, without limitation, statements
in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Actelis
Networks Inc.’s (the “Company”, “we”) financial position, business strategy and the plans and objectives
of management for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,”
“intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify
such forward-looking statements. Such forward-looking statements relate to future events or future performances, but reflect management’s
current beliefs, based on information currently available. A number of factors could cause actual events, performances or results to differ
materially from the events, performance and results discussed in the forward-looking statements. For information identifying important
factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to
Part II, Item 1A of this Quarterly Report on Form 10-Q and the Risk Factors section of our Annual Report on Form 10-K for the year ended
December 31, 2025, filed on March 18, 2026, with the U.S. Securities and Exchange Commission (the “SEC”). The Company’s
securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov.
In addition, forward-looking statements
contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:
We may not actually achieve
the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking
statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking
statements we make. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the
relevant subject. Forward-looking statements are based on our management’s current expectations, estimates, forecasts and projections
about our business and the industry in which we operate and our management’s beliefs and assumptions, and are not guarantees of
future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our
control. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we
believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements
should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information.
As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate.
The forward-looking statements
included in this Quarterly Report on Form 10-Q speak only as of the date of this filing. Although we believe that the expectations reflected
in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events
and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we assume
no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the
future. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after
the date hereof.
Recent Developments
Nasdaq Delisting
On February 4, 2026, the Company
received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC
(“Nasdaq”) indicating that the Nasdaq staff (the “Staff”) had determined to delist the Company’s securities
from The Nasdaq Capital Market. As disclosed in the Notice, the Staff determined that the Company’s common stock failed to maintain
a minimum bid price of $1.00 per share for 30 consecutive business days, in violation of Nasdaq Listing Rule 5550(a)(2) (the “Bid
Price Rule”). While companies are typically afforded a 180-calendar-day compliance period to comply with the Nasdaq Listing Rule,
the Staff concluded that the Company is not eligible for the compliance period pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv) due to
the fact that the Company effected a reverse stock split within the prior one-year period, specifically a 1-for-10 reverse stock split
on November 18, 2025, and therefore was subject to immediate delisting.
The Company requested an appeal
hearing, which stayed the suspension and delisting action. At the appeal hearing, the Company presented to the Nasdaq Hearings Panel its
plan to regain compliance with the Bid Price Rule.
On April 8, 2026, Nasdaq delivered
a letter to the Company confirming to the Company that it had denied the Company’s request for continued listing and therefore that
trading of the Company’s common stock, par value $0.0001 per share (“Common Stock”), would be suspended at the open
of trading on April 10, 2026. As a result, the Company’s Common Stock began trading on the OTCID basic market starting April 10,
2026.
On April 24, 2026, the Company
announced that it had been approved for and commenced trading on the OTCQB Venture Market operated by OTC Markets Group, effective at
the open of business on April 24, 2026. The Company’s common stock continues to trade under the symbol “ASNS.”
The OTCQB is a significantly
more limited market than the Nasdaq Capital Market, and quotation on any OTC market will result in a less liquid market for existing and
potential holders of Common Stock to trade their shares and could further depress the trading price of the Common Stock. We can provide
no assurance that the Common Stock will continue to trade on this market, whether broker-dealers will provide and continue to provide
public quotes of the Common Stock on this market, or whether the trading volume of the Common Stock will be sufficient to provide for
an efficient trading market.
We also intend to apply our
Common Stock for up-listing back onto the Nasdaq Capital Market. We do not currently meet all of the requirements for initial listing
and may not meet all of the requirements for uplisting in the future. We are working to meet all of the requirements for initial listing
in order to be approved to list our Common Stock on the Nasdaq Capital Market in the future and expect that a reverse stock split will
be necessary for us to meet the minimum bid price and/or minimum closing stock price requirements of Nasdaq. On April 13, 2026, we received
shareholder approval at a special meeting of our shareholders to conduct a reverse split of our Common Stock at a ratio between 1-for-10
and 1-for-2025, for a period of one year from the date of the special meeting. We may not be able to meet the initial listing standards
of the Nasdaq Capital Market even after a reverse stock split, we may meet such listing standards without having to affect a reverse stock
split, and/or may have our application to Nasdaq rejected.
Issuer Purchases of Equity Securities
On November 17, 2022, the
Company’s board of directors (the “Board”) authorized a stock repurchase program (the “Repurchase Program”)
pursuant to which we may repurchase up to $1.0 million of outstanding shares of our common stock. The Board authorized us to purchase
our common stock from time to time on a discretionary basis through open market or private transactions, through block trades, and pursuant
to any trading plan that may be adopted in accordance with Rule 10b-18 of the Exchange Act, and other applicable legal requirements. On
March 18, 2026, the Board authorized an expansion of the Repurchase Program, such that the maximum aggregate purchase price under the
program will now be $1.5 million.
Repurchases under the Repurchase
Program will be made at management’s discretion at prices management considers to be attractive and in the best interests of both
the Company and its stockholders, subject to the availability of stock, general market conditions, the trading price of the stock, alternative
uses for capital, and our financial performance. The Repurchase Program may be suspended, terminated or modified at any time for any reason,
including market conditions, the cost of repurchasing shares, the availability of alternative investment opportunities, liquidity, and
other factors deemed appropriate. These factors may also affect the timing and amount of share repurchases. The Repurchase Program does
not obligate us to purchase any particular number of shares. As of the date of this filing, the Company repurchased 2,674,709 shares of
its Common Stock.
Binding Term-sheet with Exaware
In March 24, 2026, the Company entered into a
binding term sheet to acquire 100% of the issued and outstanding shares of Exaware Routing Ltd. (“Exaware”), an Israel-based
provider of high-throughput routing, switching, and open networking platforms, in an all-stock transaction (the “Acquisition”). Under
the binding term sheet, the Company will acquire 100% of the equity of Exaware in an all-stock transaction. The agreed post-transaction
value ratio reflects approximately 40% attributable to the Company and 60% to Exaware, subject to third-party valuation, receipt of a
customary fairness opinion and adjustments, as well as definitive documentation. At closing, the Company expects to issue common stock
equal to 19.9% of its then outstanding number of shares, with the remaining consideration to be issued as non-voting preferred shares,
convertible into the Company’s common stock subject to compliance with applicable rules and regulations. The shares issued to Exaware
in the transaction will be subject to lock-up for a period of six months from the date of conversion of preferred shares to common stock.
The transaction is subject to the execution of a definitive agreement, board approvals, and the satisfaction of customary closing conditions.
The binding term sheet provides for a 60-day non-solicitation and no-shop period, and includes the payment of a break-up fee under specified
circumstances. The Company and Exaware remain engaged in ongoing discussions to advance the Acquisition towards definitive agreement and closing.
The table below provides our results of operations for the periods indicated.
Three and Six Months Ended MarchJune 31,30, 20262026, Compared
to Three and Six Months Ended MarchJune 31,30, 2025
Our revenues for the three months ended MarchJune 31,30, 20262026, amounted to
$958,000 $1.1 million, compared to $721,000approximately $0.9 million for the three months ended MarchJune 31,30, 2025. The increase was primarily attributable to an expansion of the
Company’s sales footprint, including delivery of a renewal order to a large U.S. carrier for software and Asiaservice Pacificas orderswell as to carriers,other federalcarriers andin ITS customers,EMEA, with
revenue increases of 25%33% in North America, 27%22% in Europe, the Middle East and Africa, and substantially in the Asia-Pacific region.Africa.
Our revenues for the six months ended June 30, 2026, amounted to $2 million, compared to approximately $1.7 million for the six months ended June 30, 2025. The increase was primarily attributable to an expansion of the Company’s sales footprint, including delivery of a renewal order to a large U.S. carrier for software and service , with revenue increases of 39% in North America, 15% in Europe, the Middle East and Africa.
Our cost of revenues for the three months ended June 30, 2026, amounted to $0.6 million, compared to approximately $0.6 million for the three months ended June 30, 2025. The expense remained consistent with the prior-year period despite higher revenue, primarily due to an improved software sales mix and higher gross margins.
Our cost of revenues for the threesix months ended MarchJune 31,30, 2026, amounted
to $723,000$1.3 million, compared to approximately $470,000$1.1 million for the threesix months ended MarchJune 31,30, 2025. The increase was primarily attributable to higher
direct costssales drivenvolume byduring deliverythe ofperiod an unusually low margin dealand in the US of approximately $200,000 that is not representative of our
normal profitability, and indirect costs increase associatedline with foreignthe exchange rate, inventory and warranty related costs which. The
increase in directrevenue costsand wassoftware offsetrevenue by higher revenue.mix.
Our research and development
expenses for the three months ended MarchJune 31,30, 20262026, amounted to $689,000$0.7 million, compared to $681,000$0.7 million for the three months ended MarchJune 31,30, 2025.
The increaseCompany was primarily attributable to unfavorable foreign exchange movements, increasing expenses by approximately $66,000, and was
partially offset byimplemented cost reduction measures implementedduring the period; however the resulting savings were offset by management.the unfavorable impact of foreign exchange rate fluctuations.
Our research and development expenses for the six months ended June 30, 2026, amounted to $1.3 million, compared to $1.4 million for the six months ended June 30, 2025. The Company implemented cost reduction measures during the period; however, the resulting savings were significantly offset by the unfavorable impact of foreign exchange rate fluctuations.
Our sales and marketing expenses
for the three months ended March 31, 2026 amounted to $675,000 compared to $666,000 for the three months ended MarchJune 31,30, 2025.2026, The increase
is relatedamounted to increase$0.8 million, compared to $0.7 million for the three months ended June 30, 2025 driven by investments in new sales resources for the Federal market and marketing, and higher commission payout due to salespersonshigher inrevenues. lineAt withthe increasesame intime, revenues, as well as unfavorable foreign exchange movements,
increasing expenses by approximately $30,000. The increase was partially offset bysome cost reduction measures were implemented that were offset by management.the unfavorable impact of foreign exchange rate fluctuations.
Our sales and marketing expenses for the six months ended June 30, 2026, amounted to $1.4 million, compared to $1.4 million for the six months ended June 30, 2025. The investments in new resources, higher commission payout due to higher revenues and unfavorable impact of foreign exchange rate fluctuations were offset by cost reduction measures during the period.
Our general and administrative
expenses for the three months ended MarchJune 31,30, 20262026, amounted to $734,000$0.7 million, compared to $716,000$0.7 million for the three months ended MarchJune 31,30, 2025.
The increase was primarily attributable to unfavorable foreign exchange movements, increasing expenses byremained approximatelyunchanged $29,000.because The increase
was partially offset bythe cost reduction measures implemented during the period with the help of AI and other operating measures were offset by the Company.unfavorable impact of public Company expenses and foreign exchange rate fluctuations.
Our general and administrative expenses for the six months ended June 30, 2026, amounted to $1.5 million, compared to $1.4 million for the six months ended June 30, 2025. Similar to the three month period ended June 30, 2026, cost reduction measures implemented during the period with the help of AI and other operating measures were partially offset by unfavorable impact of public Company expenses and foreign exchange rate fluctuations.
Operating (Loss) Income
Our operating loss for the
three months ended MarchJune 31,30, 2026, was approximately$1.6 $1.86 millionmillion, compared to an operating loss of approximately $1.81$1.8 million for the
three months ended MarchJune 31,30, 2025. The increasedecrease in loss was primarily drivenattributable byto anincreased increase in the cost of goodsrevenues and unfavorableresulting foreignhigher exchange
movements,gross partiallymargin, offsetcoupled by revenue increase andwith cost reduction measures implemented during the period, partially offset by the Company.investment in sales and marketing, and the unfavorable impact of foreign exchange rate fluctuations, amounting to approximately $150,000.
Our operating loss for the six months ended June 30, 2026, was $3.4 million, compared to an operating loss of approximately $3.6 million for the six months ended June 30, 2025. The decrease was primarily attributable to increased revenues and resulting higher gross margin coupled with the cost reduction measures implemented during the period, almost entirely offset by the unfavorable impact of foreign exchange rate fluctuations amounting to approximately $280,000.
Other Financial expenses,Expenses, netNet and Interest Expenses
Our financial income, net for the three months ended June 30, 2026, was $189,000(including $106,000 interest expenses) compared to financial expense, net of $128,000 (including $22,000 interest expenses) for the three months ended June 30, 2025. Financial expenses reflected a $400,000 gain from the change in the fair value of pre-funded warrants classified as liabilities, which was substantially offset by foreign exchange losses, primarily due to fluctuations in the NIS against the U.S. dollar.
Our financial expense, net
for the threesix months ended MarchJune 31,30, 2026, was $593,000$404,000 (including $120,000 interest expenses) compared to $48,000financial expense, net of $176,000 (including $56,000 interest expenses) for the threesix months ended MarchJune 31,30, 2025. Our financial expenses
net, mainly consisted of interest expenses, exchange rate differences of certain currencies (including NIS against USD). DuringIn the three
months ended in March 31, 20262026, we recorded a financial expense of $625,000 as a result of the increase in the commitment fee under the
common stock purchase agreement associated with our equity line of credit, payable in common shares issuance. This increase in expense
was partially offset by income of $124,000$530,000 resulting from changes in the fair value of pre-funded warrants classified as a liability.
Please see Note 6(b) to the condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q for
more information.
Our net loss for the three months ended June 30, 2026 was $1.4 million, or $(0.05) per basic and diluted share, compared to net loss of approximately $1.9 million, or $(2.08) per basic and diluted share for the three months ended June 30, 2025. The decrease was primarily due to higher sales, improved gross margins, and continued efforts to reduce operating expenses as well as income from the reduction in warrant liability fair value. These favorable factors were partially offset by the adverse impact of foreign exchange rate.
Our net loss for the six months ended June 30, 2026 was $3.8 million, or $(0.19) per basic and diluted share, compared to net loss of approximately $3.8 million, or $(4.26) per basic and diluted share for the six months ended June 30, 2025. The net loss remained relatively unchanged compared to the prior year six months, as improvements in sales, gross margins, and operating expense management were offset by unfavorable foreign exchange rate impact as well as financial expenses associated with warrants granted.
Our net loss for the three
months ended March 31, 2026 was approximately $2.5 million, compared to net loss of approximately $1.9 million for the three months ended
March 31, 2025. This increase was primarily due to additional fees of $625,000 related to the Commitment Fee under the Common Stock Purchase
Agreement payable in common shares issuance and foreign exchange rate differences, partially offset by income of $124,000 resulting from
changes in the fair value of pre-funded warrants classified as a liability, revenue increase and cost reduction measures implemented by
the Company.
Non-GAAP Adjusted EBITDA and
Adjusted EBITDA margin are Non-GAAP financial measures. In addition to reporting financial results in accordance with GAAP, we provide
Non-GAAP supplemental operating results adjusted for certain items, including: financial expenses, which are interest, financial instrument
fair value adjustments, exchange rate differences of assets and liabilities, stock-basedShare based compensation expenses, depreciation and amortization
expense, tax expense, and impact of development expenses ahead of product launch. We adjust for the items listed above and show non-GAAP
financial measures in all periods presented, unless the impact is clearly immaterial to our financial statements. When we calculate the
tax effect of the adjustments, we include all current and deferred income tax expense commensurate with the adjusted measure of pre-tax
profitability.
Our future capital requirements
will be affected by many factors, including our revenuerevenues and resulting gross margin growth, the timing and extent of investments to support such growth,growth compared to our resulting increase in revenues and gross margin, the associated expansion
of sales and marketing activities, increases or decreases in general and administrative costs, repayment of principal of our existing credit line,
working capital to support securing raw material supply and many other factors as described under “Risk Factors.” At the same time, our investments, including in sales and marketing, as well as the cost reduction measures we are taking, are aimed at the goal of reaching the break even point on our P&L and resulting cash flow.
To the extent additional funds
are necessary to meet our long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will
be obtained through the incurrence of additional indebtedness, additional equity financings or a combination of these potential sources
of funds; however, such financing may not be available on favorable terms, or at all. In particular, our delisting from the warNasdaq Capital Market to the OTCQB limits our ability to raise equity, which will remain limited if we are unsuccessful in Israelre-listing on Nasdaq. Additionally, the wars in the Middle East and the war between
Russia and the Ukraine, hashave resulted in, and may continue to result in, significant disruption of global financial markets, reducing our
ability to access capital.
On September 18, 2024, we
filed a shelf registration statement on Form S-3 (the “Registration Statement”). Pursuant to the Registration Statement, we
may offer and sell securities having an aggregate public offering price of up to $50.0 million. In connection with the filing of the Registration
Statement, on September 25, 2024, we entered into a sales agreement with H.C. Wainwright & Co. (the “Sales Agent”),
pursuant to which we may issue and sell shares of our common stock for an aggregate offering price of up to $3.4 million under an at-the-market offering
program (the “ATM”), which is included in the $50.0 million of securities that may be offered pursuant to the Registration
Statement. Pursuant to the ATM, we will pay the Sales Agent a commission rate of up to 3.0% of the gross proceeds from the sale of any
shares of our common stock. We are not obligated to make any sales of shares under the ATM.
In March 2025, we increased the at-the-market equity program by an
additional $1.3 million. In January 2026, we increased the at-the-market equity program by an additional $12 million. As of March 31,
2026, we have sold 18,429,137 shares of our common stock and received approximately $6.9 million in net proceeds under the ATM, and we
had approximately $4.7 million available for future offerings under the prospectus filed with respect to the ATM. The Company is currently
unable to utilize its ATM facility as a result of its delisting from Nasdaq until it will be able to relist.
Under the Repurchase Program,
during the quarter ended March 31, 2026, the Company purchased 2,674,709 shares of its common stock, for a total price of approximately
$1 million.
As discussed in Note 1(b)
to the condensed consolidated financial statements appearing elsewhere in this Quarterly report on Form 10-Q, we have incurred significant
losses and negative cash flows from operations and incurred losses of approximately $2.5 million and approximately $1.86$3.8 million for the
three six months ended MarchJune 31,30, 2026 and 2025, respectively.2025. During the threesix months ended MarchJune 31,30, 2026 and 2025, we had negative cash
flows from operations of $1.9$3.6 million and $2.2$3.2 million, respectively.
As of MarchJune 31,30, 2026, we had
an accumulated deficit of $54.8$56.2 million, cash on hand (including short term deposits and restricted cash equivalents) of $7.5approximately million,
$5.7 million and long-term restricted cash and cash equivalentsdeposits and restricted bank deposits of $0.2$159 million.as of June 30, 2026. We monitor our cash flow projections
on a current basis and take active measures to obtain the funding we require to continue our operations. However, these cash flow projections
are subject to various uncertainties concerning their fulfillment, such as the ability to increase revenues due to lack of customers or
decrease cost structure. Our transition to profitable operations is dependent on generating a level of revenue adequate to support our
cost structure through growth of existing and new customers.
Amendment to Equity Line of Credit
On September 27, 2025, we entered into common stock purchase agreement (the “ELOC Purchase Agreement”), with an effective date of October 1, 2025 (the “Commencement Date”), and the registration rights agreement (the “White Lion RRA”) with White Lion Capital LLC, a Nevada limited liability company (“White Lion”). Pursuant to the ELOC Purchase Agreement, the Company has the right, but not the obligation to require White Lion to purchase, from time to time, up to $30,000,000 (the “Commitment Amount”) in aggregate gross purchase price of newly issued shares of the Company’s common stock for the 36-month period beginning on the Commencement Date, subject to certain limitations and conditions set forth in the ELOC Purchase Agreement.
As consideration for White Lion’s irrevocable commitment to purchase the Company’s common stock up to the Commitment Amount, the Company agreed to issue commitment shares (“Commitment Shares”) equal to the commitment amount of $750,000 (the “Commitment Fee Amount”) divided by the lowest traded price of the Company’s common stock during the 30 business days prior to the issuance of the commitment shares.
If at any point during the term of the ELOC Purchase Agreement the Company failed to be listed on the Nasdaq Capital Market, the Commitment Fee Amount will increase to $1,000,000 if remedied within six months or less, to $1,250,000 if remedied after six months but before twelve months, and $1,500,000 if not remedied within twelve months (the “Delisting Penalty Provision”).
Subject to the satisfaction of certain customary conditions including, without limitation, the effectiveness of a registration statement registering the shares issuable pursuant to the ELOC Purchase Agreement, the Company’s right to sell shares to White Lion will commence on the Commencement Date and extend until 36 months through the Commitment Period, unless the Company has exercised its right in full to sell shares to White Lion under the ELOC Purchase Agreement prior to such date. During such term, subject to the terms and conditions of the ELOC Purchase Agreement, the Company shall notify White Lion through a purchase notice (“Purchase Notice”) when the Company exercises its right to sell shares (the effective date of such notice, a “Notice Date”). The Purchase Notice may be a Regular Purchase Notice or a Rapid Purchase Notice, each as described in the form of ELOC Purchase Agreement. In the event the Company was delisted from the Nasdaq Capital Market, White Lion would only be obligated to make any Purchase Notices at a value equal to $0.0001 per share of common stock (the “Delisting Purchase Notice Mechanism”). On April 10, 2026, the Company was delisted from the Nasdaq Capital Market triggering the Delisting Purchase Notice Mechanism.
On July 1, 2026, the Company and White Lion entered into the Amendment to the ELOC Purchase Agreement pursuant to which the Company agreed to issue to White Lion an aggregate of 9,850,000 shares of common stock (the “Amendment Commitment Securities”) in exchange for White Lion’s right to receive shares of common stock under the Commitment Shares provisions and the Delisting Penalty Provision due to the Company’s delisting from the Nasdaq Capital Market in April 2026. The Amendment Commitment Securities is comprised of (i) 3,000,000 shares of common stock, (ii) 3,850,000 pre-funded warrants (“Amendment Commitment Pre-Funded Warrants”), and (iii) 3,000,000 common warrants (“Amendment Commitment Common Warrants”).
The Amendment Commitment Pre-Funded Warrants will have an initial exercise date at the earlier of (i) the effective date of a reverse stock split of the Company’s common stock, and (ii) the effective date of an increase in the Company’s authorized share count sufficient for the issuance of the shares underlying the Amendment Commitment Pre-Funded Warrants (the “Pre-Funded Warrant Initial Exercise Date”). The exercise price of the Amendment Commitment Pre-Funded Warrants is $0.0001 per share, and the warrants shall be exercisable from the Pre-Funded Warrant Initial Exercise Date until exercised in full.
The Amendment Commitment Common Warrants will have an initial exercise date on the date on which the Company successfully lists its common stock on an “Eligible Market”, as such term is defined in the Amendment Commitment Common Warrants (the “Common Warrant Initial Exercise Date”). The exercise price of the Amendment Commitment Common Warrants is $0.20 per share, and the warrants shall be exercisable until the eighteen month anniversary of the Common Warrant Initial Exercise Date.
In addition, pursuant to the ELOC Purchase Agreement Amendment, the Company and White Lion agreed to remove the Delisting Purchase Notice Mechanism and replace it with amended purchase notice mechanisms which will allow the Company to more effectively utilize Purchase Notices under the ELOC Purchase Agreement while the Company remains delisted from the Nasdaq Capital Market.
Under an amended Rapid Purchase Notice Option 1, the purchase price to be paid by White Lion shall mean (a) ninety-seven percent (97.0%) multiplied by the lowest traded price of the common stock on Rapid Purchase Notice Date, minus (b) $0.005 (provided that, notwithstanding anything in the ELOC Purchase Agreement to the contrary, if the Company, at any time, combines (by any reverse stock split, stock dividend, stock combination, recapitalization, or other similar transaction) one or more classes of its outstanding common stock into a smaller number of shares, the $0.005 amount shall not be proportionately increased or otherwise adjusted).
Under an amended Rapid Purchase Notice Option 2, the purchase price to be paid by White Lion shall mean (a) ninety-seven percent (97.0%) multiplied by the lowest traded price of the common stock two hours following the written confirmation of the acceptance of the Rapid Purchase Notice by White Lion, minus (b) $0.005 (provided that, notwithstanding anything in the ELOC Purchase Agreement to the contrary, if the Company, at any time, combines (by any reverse stock split, stock dividend, stock combination, recapitalization, or other similar transaction) one or more classes of its outstanding common stock into a smaller number of shares, the $0.005 amount shall not be proportionately increased or otherwise adjusted).
Under an amended Regular Purchase Notice Option, the purchase price to be paid by White Lion shall mean shall mean (a) (i) ninety-seven percent (97.0%) multiplied by the lower of (i) the lowest daily VWAP of the common stock during the Regular Purchase Valuation Period (as such term is defined in the ELOC Purchase Agreement) or (ii) the closing price of common stock one Business Day prior to the delivery of the applicable Regular Purchase Notice, minus (b) $0.005 (provided that, notwithstanding anything in the ELOC Purchase Agreement to the contrary, if the Company, at any time, combines (by any reverse stock split, stock dividend, stock combination, recapitalization, or other similar transaction) one or more classes of its outstanding common stock into a smaller number of shares, the $0.005 amount shall not be proportionately increased or otherwise adjusted).
ASNS insider buying and selling (Form 4)
Since 2026-04-11, insiders reported open-market purchases in 0 Form 4 filings and open-market sales in 2 filings (2 insiders, 3 trade dates, 224,362 shares, about $15.8K). Net open-market shares: -224,362 (purchases minus sales); net value about -$15.8K.Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.
| Trade date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-07-24 | White Lion Capital Llc |
Open-market sale | 130,112 | $0.07 | $9.1K |
| 2026-07-23 | White Lion Capital Llc |
Open-market sale | 80,449 | $0.07 | $5.6K |
| 2026-05-18 | Barlev Tuvia |
Open-market sale | 13,801 | $0.08 | $1.1K |
Well-known investors holding ASNS (13F)
None of the 59 investors we track reported a position in their latest 13F.